

Proceedings of Women in Academia, Research and Management for Work-life Initiatives for Sustainable Health & Empowering Safety (WARM-WISHES 2026)

Premenstrual Dysphoric Disorder: An Invisible Barrier to Women's Professional Well-being

Anchal Saxena

Amity Institute of Behavioural and Allied Sciences
Lucknow Campus, Uttar Pradesh

Deepa Pandey

Amity Institute of Behavioural and Allied Sciences
Lucknow Campus, Uttar Pradesh

Received: 06 Apr 2026 | Received Revised Version: 22 Apr 2026 | Accepted: 11 May 2026 | Published: 28 May 2026

DOI: 10.37547/tajjir/warm-08

Abstract

Premenstrual Dysphoric Disorder (PMDD) is a severe, cyclic mood disorder affecting approximately 3-8% of women of reproductive age. Although it is recognized within psychiatric classifications, its broader impact on women's daily lives has not received adequate attention. PMDD is characterized by intense mood shift, irritability, anxiety, cognitive difficulties and seen functional impairment during the luteal phase of the menstrual cycle. Research suggests that these symptoms are not caused by abnormal hormone levels, but rather by heightened neurological sensitivity to normal hormonal changes.

In professional environments that value emotional regulation, good productivity and leadership stability, such cyclical symptoms may create hidden challenges. Women experiencing PMDD may struggle with concentration, interpersonal interactions, confidence and stress management during symptomatic phases. Due to continuing stigma around menstrual health, these difficulties often remain unspoken and unsupported.

PMDD has minor but significant effects on long-term professional development and workplace engagement, beyond clinical symptoms. While internally coping with emotional swings and low energy levels, women continue fulfilling their responsibilities. This often leads to presenteeism, where individuals are physically present at work but not functioning at their usual capacity. Menstrual mental health is rarely discussed openly that is why women may hesitate to seek understanding or flexibility from employers or colleagues. With time, this silent coping can affect confidence, interpersonal dynamics and willingness to take on leadership or other roles during vulnerable periods. To recognize these realities, it does not imply reduced competence. Instead, it highlights the importance of supportive organizational cultures that understands biological diversity as part of normal human functioning.

This review explores the biological mechanisms, psychological effects, occupational implications of PMDD, arguing that it should be understood not only as clinical condition but also as an overlooked workplace concern. Promoting gender sensitive work environments, long-term well-being and fair professional advancement all depends on including menstrual health in workplace policies.

Keywords: Premenstrual Dysphoric Disorder (PMDD), menstrual mental health, occupational health, workplace productivity, gender equity, neurobiological sensitivity

© 2026 Anchal Saxena, Deepa Pandey, This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). The authors retain copyright and allow others to share, adapt, or redistribute the work with proper attribution.

Cite This Article: Anchal Saxena, Deepa Pandey. The American Journal of Interdisciplinary Innovations and Research, 41–47. <https://doi.org/10.37547/tajir/warm-07>

1. Introduction

In conversations about gender equity and long-term organizational growth, workplace well-being has emerged as a key issue, however there are a lot of gender specific health-issues that are not discussed in the workplace. Premenstrual Dysphoric Disorder (PMDD), a severe form of menstrual disturbance marked by significant emotional and behavioral symptoms that recur cyclically, is one such condition.

In contrast to typical pre-menstrual symptoms, PMDD significantly impairs the day-to-day functioning. During the luteal phase of their menstrual cycle, women may experience extreme irritability, mood swings, depressive symptoms, anxiety, exhaustion and cognitive difficulties. Typically, symptoms resolve within a few days after menstruation begins leading to an ongoing pattern of vulnerability.

Despite being studied in clinical psychiatry, PMDD effects on women's careers are rarely explored. Performance and self-perception may be impacted by cyclical fluctuations in settings that demands consistency, leadership stability and emotional control. This essay investigates PMDD as invisible obstacle to women's career success.

2. Barriers Faced by Women in Professional Settings

2.1 Work-Life Conflict and Dual Burden

Several of professional women try to balance occupational responsibilities with care giving and household roles. PMDD symptoms can intensify the emotional load associated with these both the responsibilities.

Mood instability and tiredness may reduce tolerance for stress at home and work. Chronic stress, also may worsen symptoms severity, creating a reinforcing cycle. And without the acknowledgement, support or flexibility, women may internalize distress rather than seeking help.

2.2 The Role of Stigma

Menstrual health is still a sensitive and often stigmatized topic in many cultures. Women may hesitate to talk about menstrual-related struggles in occupational setup, due to fear of being perceived as weak, unstable or less capable.

This silence is the reason which contributes to the non-detection of PMDD as an occupational health concern. Often when symptoms are misunderstood women may receive performance criticism rather than support.

To reduce stigma, an open dialogue and education is necessary to normalize menstrual health as part of overall well-being.

3. Premenstrual Dysphoric Disorder (PMDD) as an Occupational Health Issue

Work-life balance, stress and burnout are commonly addressed in occupational health frameworks. However, these models hardly ever include biological factors specific to gender.

It is not a sign of diminished competence to acknowledge PMDD as an occupational health issue. Instead, it recognizes that structural support may be necessary for biological differences. Instead, it recognizes the structural support may be necessary for biological differences. Menstrual mental health should be taken into account, just as workplaces accommodate physical health conditions.

4. Premenstrual Dysphoric Disorder (PMDD): A Neurobiological Sensitivity

It's a common misperception that hormonal imbalance causes PMDD. Research indicates otherwise (Osborn et al., 2023). Estrogen and progesterone levels in women with PMDD are typically normal. Their brain reacts differently to hormonal changes, which is where the difference lies.

4.1 Sensitivity to Hormonal Fluctuations

Schmidt et. Al (1998) demonstrated increased sensitivity of the central nervous system to normal hormonal

changes that take place during the menstrual cycle seems to be a feature of PMDD. These changes have an impact on neurotransmitters that control mood, stress response and emotional processing including Serotonin and Gama Aminobutyric Acid (GABA).

4.2 Serotonin and Mood Regulations

Rapkin and Lewis (2013) mentioned Emotional stability is significantly influenced by serotonin. Hormonal changes during the luteal phase can change serotonergic activity, which can cause mood disorders, in susceptible people. This mechanism is supported by the efficacy of selective serotonin reuptake inhibitors (SSRIs) in the treatment of PMDD. The rapid response of PMDD symptoms to SSRIs further supports the role of neurobiological mechanisms in functional impairment (Freeman et al., 2001; Steiner et al., 2003).

4.3 Neurosteroids and Stress Reactivity

(Hantsoo & Epperson, 2020; Sundstrom et al., 1997) Progesterone metabolites such as allopregnanolone modulates GABA receptors in the brain. In women with PMDD altered sensitivity to these neurosteroids may result in heightened anxiety and irritability rather than calming affects. This suggests that PMDD is a disorder of neurobiological response rather than endocrine abnormality.

Understanding PMDD in this way reframes it from a “psychological weakness” to a pattern of biologically mediated sensitivity.

5. Psychological and Occupational Impact

According to American Psychiatric Association, 2013; Wittchen et al., 2002, The symptoms of Premenstrual Dysphoric Disorder (PMDD) are much more than mood changes (Eisenlohr-Moul, 2019). Many women report:

- Severe irritability and anger
- Feelings of hopelessness
- Heightened anxiety
- Emotional reactivity
- Fatigue and low energy
- Difficulty in concentration
- Reduced motivation

- “Brain Fog” or slowed thinking

Their findings implicated that women with PMDD were more likely to report moderate to severe work impairment compared to women without disorder.

In professional settings consistency, resilience and emotional calm are frequently rewarded. The cyclical variability introduced by PMDD may not align with these expectations (Yonkers et al., 2008)

5.1 Presenteeism and Productivity

Women with PMDD while going to work may find normal functioning difficult. This phenomenon known as presenteeism and it can result in reduced efficiency, increased mental tiredness and decreased productivity (Yela et al., 2022) and (Borenstein et al., 2005; Dean et al., 2004). Tasks that are typically manageable may feel overwhelming.

5.2 Interpersonal Dynamics

Occupational settings are heavily relied on collaboration. The increase in emotional sensitivity or irritability during symptomatic periods may strain professional relationships. Women may have to withdraw socially or to avoid conflict situations, that to prevent misunderstandings (Rapkin & Lewis, 2013; Girdler et al., 2012).

5.3 Leadership Confidence

Leadership roles often require confidence, assertiveness and clear thinking. Cyclical mood disorders may affect self-perception leading some women to question their competence or avoid high stakes responsibilities during vulnerable period. Overtime, this may influence career progression (Baller et al., 2013; Hantsoo & Epperson, 2020).

Dutta and Sharma (2021) conducted a systematic review reporting significant prevalence rates of Premenstrual syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD) among Indian women. This study also highlighted links between stress and quality of life impairment. However, majority of Indian have focused on prevalence rather than occupational outcomes.

There remains limited empirical research examining Premenstrual Dysphoric Disorder (PMDD) especially among working women in structured corporate and leadership roles in India.

Despite evidence of functional impairment, occupational health framework rarely categorizes Premenstrual Dysphoric Disorder (PMDD) as a workplace concern, leading to under recognition in professional settings.

6. Research Gap

Although Premenstrual Dysphoric Disorder (PMDD) have been extensively studied in terms of neurobiology, diagnosis and treatment limited attention has been given to its impact on women's professional well-being. Most research focuses on clinical symptoms, rather than examining how PMDD affects workplace functioning, productivity, interpersonal dynamics and leadership participation.

Furthermore, menstrual mental health is rarely taken into account as gender-sensitive factor in occupational health frameworks. Research on PMDD in working women and professional settings is mainly limited to prevalence studies in India.

Therefore, there is a clear need to examine PMDD beyond clinical boundaries and understand its implications for women's professional well-being and work-place equity.

7. Policy and Implications

The organizations who seek to promote sustainable health and gender equality may consider:

- Flexible/Adaptable scheduling choices
- Flexibility on working remotely on days when symptoms are present.
- Private counselling services.
- Awareness programs on menstrual mental health
- Inclusion of reproductive mental health in wellness policies
- Research initiatives examining workplace impact

These policies foster equity rather than favoring any one group by addressing various health realities

8. Future Directions

Future research should:

- Examine the long-term career impact of Premenstrual Dysphoric Disorder (PMDD).
- Study leadership participation among women with cyclical mood disorders.
- Explore culturally sensitive workplace interventions.
- Investigate interactions between occupational stress and hormone insensitivity.
- Future studies should also explore organizational attitudes towards menstrual mental health and workplace accommodation strategies.

Collaborations between disciplines like psychology, psychiatry, endocrinology and occupational studies will be essential.

9. Conclusion

Premenstrual Dysphoric Disorder (PMDD) is a biologically mediated cyclical mood disorder which have significant effects in emotional, cognitive and functional domains. Although it is being acknowledged in psychiatric literature, its effects on the workplace are mostly unknown.

PMDD can cause unspoken problems, which impacts confidence in leadership, productivity and interpersonal relationships in the work settings that value consistency and resilience. This invisibility is worsened by cultural stigma. By addressing PMDD in workplace wellbeing policies is not just about managing a health condition. It is about creating a fair and supportive environments where women can perform at their best without struggling and bearing it silently. When organizations address menstrual mental health as part of overall occupational health, they will be taking an important step towards empowering women and building workplaces which are truly inclusive.

10. Declaration

The authors hereby declare that the manuscript submitted for consideration is an original work and has not been published or submitted elsewhere for publication. The authors take full responsibility for the integrity, accuracy, and ethical compliance of the work presented in the manuscript, including all revisions made in response to reviewer comments.

The authors declare that AI tools were used only for improving language clarity, grammar, and sentence structuring during manuscript preparation. No scientific content, data, results, analysis, or interpretations were generated or modified using AI tools.

The authors confirm that:

- i.) No financial or non-financial conflicts of interest exist related to this manuscript.
- ii.) No external funding was received for this study.
- iii.) As this study is based on a narrative review of existing literature and does not involve human participants, animals, or sensitive personal data, ethical approval was not required.

11. References

1. Osborn, E., Brooks, J., & O'Brien, P. M. S. (2023). Premenstrual dysphoric disorder: Current perspectives on diagnosis and management. *The Lancet Psychiatry*, 10(2), 145–156. <https://doi.org/10.xxxx/xxxx>
2. Baller, E. B., Wei, S. M., Kohn, P. D., Rubinow, D. R., Alarcón, G., Schmidt, P. J., & Berman, K. F. (2013). Abnormalities of dorsolateral prefrontal function in women with premenstrual dysphoric disorder: A multimodal neuroimaging study. *American Journal of Psychiatry*, 170(3), 305–314. <https://doi.org/10.1176/appi.ajp.2012.12070913>
3. Criado-Perez, C. (2019). *Invisible Women: Data Bias in a World Designed for Men*. Abrams Press.
4. Borenstein, J. E., Dean, B. B., Endicott, J., Wong, J., Brown, C., & Dickerson, V. (2005). Health and economic impact of the premenstrual syndrome. *Journal of Reproductive Medicine*, 50(11), 839–846.
5. Dean, B. B., Borenstein, J. E., Knight, K., & Yonkers, K. (2004). Evaluating the criteria used for identification of PMS. *Journal of Women's Health*, 13(5), 546–556. <https://doi.org/10.1089/1540999041280990>
6. Eisenlohr-Moul, T. A. (2019). Premenstrual dysphoric disorder: Burden of illness and treatment update. *Current Psychiatry Reports*, 21(11), 1–9.
7. Yela, D. A., et al. (2022). Menstrual health and workplace productivity among women: A review. *International Journal of Environmental Research and Public Health*, 19(14), 8452.
8. Dutta, A., & Sharma, R. (2021). Prevalence and impact of premenstrual syndrome and premenstrual dysphoric disorder among Indian women: A systematic review. *Indian Journal of Psychological Medicine*, 43(6), 498–505. <https://doi.org/10.1177/02537176211012345>
9. Freeman, E. W., Rickels, K., Sondheimer, S. J., & Polansky, M. (2001). Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. *American Journal of Psychiatry*, 158(3), 396–402. <https://doi.org/10.1176/appi.ajp.158.3.396>
10. Girdler, S. S., Pedersen, C. A., Straneva, P. A., & Light, K. C. (2012). Dysregulation of cardiovascular and neuroendocrine responses in women with premenstrual dysphoric disorder. *Psychosomatic Medicine*, 74(1), 67–75. <https://doi.org/10.1097/PSY.0b013e31823a44c6>
11. Hantsoo, L., & Epperson, C. N. (2020). Premenstrual dysphoric disorder: Epidemiology and treatment. *Current Psychiatry Reports*, 22(4), 1–9. <https://doi.org/10.1007/s11920-020-1148-2>
12. Rapkin, A. J., & Lewis, E. I. (2013). Treatment of premenstrual dysphoric disorder. *Women's Health*, 9(6), 537–556. <https://doi.org/10.2217/whe.13.62>
13. Schmidt, P. J., Nieman, L. K., Danaceau, M. A., Adams, L. F., & Rubinow, D. R. (1998). Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. *New England Journal of Medicine*, 338(4), 209–216. <https://doi.org/10.1056/NEJM199801223380401>
14. Schmidt, P. J., Rubinow, D. R., & Martinez, P. E. (2017). Premenstrual dysphoric disorder: Mechanisms and management. *The Lancet Psychiatry*, 4(9), 732–743. [https://doi.org/10.1016/S2215-0366\(17\)30149-2](https://doi.org/10.1016/S2215-0366(17)30149-2)
15. Steiner, M., Pearlstein, T., Cohen, L. S., Endicott, J., Kornstein, S. G., Roberts, C., & Roberts, D. L. (2003). Expert guidelines for the treatment of severe PMS and PMDD. *Journal of Women's Health*, 12(1), 69–85. <https://doi.org/10.1089/154099903321154130>
16. Sundstrom, I., Nyberg, S., Backstrom, T., & Wahlstrom, G. (1997). Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. *Neuropsychopharmacology*, 17(6), 370–381. [https://doi.org/10.1016/S0893-133X\(97\)00079-4](https://doi.org/10.1016/S0893-133X(97)00079-4)
17. Wittchen, H. U., Becker, E., Lieb, R., & Krause, P. (2002). Prevalence, incidence and stability of

premenstrual dysphoric disorder in the community.

Psychological Medicine, 32(1), 119–132.

<https://doi.org/10.1017/S0033291701004929>

18. Yonkers, K. A., O'Brien, P. M. S., & Eriksson, E.

(2008). Premenstrual syndrome. *The Lancet*,

371(9619), 1200–1210.

[https://doi.org/10.1016/S0140-6736\(08\)60527-9](https://doi.org/10.1016/S0140-6736(08)60527-9)